Pallas Health vs BreezeMeds: Online GLP-1 options compared

Quick verdict: For a clinician-led choice between brand-name pens and US-compounded GLP-1, Pallas Health emphasizes one all-in plan price and a $139 first month for compounded semaglutide. BreezeMeds highlights multiple formats including injectable and oral options with semaglutide starting at $199.

How Pallas Health and BreezeMeds differ at a glance

This comparison of Pallas Health vs BreezeMeds focuses on the most distinctive supported differences: medication routes and choice, pricing structure and introductory pricing, compounded medicine disclosures and regulatory notes, clinician review and plan inclusions, and shipping plus renewal cadence. Both providers state treatment is subject to clinician review and availability by state where applicable.

Medication options and clinician selection

Pallas Health offers FDA-approved brand-name Wegovy, Ozempic, Zepbound and Mounjaro plus clinician-personalized compounded semaglutide or tirzepatide prepared in the USA when a brand medication is not the right fit. BreezeMeds lists semaglutide and tirzepatide in injectable and oral forms. Pallas presents both brand and compounded routes from one intake with a US-licensed clinician determining eligibility. BreezeMeds emphasizes injectable and oral options and notes treatment is available only when a licensed clinician determines it is medically appropriate.

Pricing and introductory offers

Pallas advertises compounded semaglutide at $139 for the first month, then $597 every 12 weeks, a $199 per month average; compounded tirzepatide is $179 first month then $897 every 12 weeks, a $299 per month average. Pallas also lists cash-pay brand prices for Wegovy, Zepbound, Ozempic and Mounjaro but notes pricing can change and to confirm at checkout. BreezeMeds displays starting prices for multiple formats: semaglutide injection starting at $199 per month, tirzepatide injection starting at $299, and oral semaglutide and oral tirzepatide displayed from $399; a separate $169 figure appears without a clear product association. BreezeMeds advises confirming eligibility, medication, total cost, renewal terms and state availability before enrollment.

Compounding, approvals and regulatory notes

Pallas explicitly states compounded medications are not FDA-approved and are prepared by US-licensed compounding pharmacies; the medication received may differ in appearance from site images. The Pallas landing notes compounding is used when a brand medication is not the right fit and warns compounded medications are not FDA-reviewed for safety effectiveness or quality. BreezeMeds similarly notes that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. Both providers require clinician determination of appropriateness.

Plan inclusions, renewals and service model

Pallas markets one all-in plan price that includes clinician review, ongoing check-ins and care-team messaging with no membership fee. Compounded plans renew every 12 weeks and Pallas notes cancellation timing matters because of that cadence. Pallas is 100 percent online and asynchronous in most states with a video visit required in seven states plus Washington D.C. BreezeMeds lists online intake, a personalized treatment plan and discreet home delivery. BreezeMeds captured content does not fully reveal fees, renewal terms or whether plans are billed monthly or by multiweek cycles, prompting the guidance to confirm costs and renewal terms before enrolling.

Side-by-side comparison table

What the captured evidence does not show

Neither source capture provides insurance billing details beyond Pallas stating it does not bill insurance and is cash-pay only. BreezeMeds captured content does not show full fee schedules, renewal cadence for each product, or expanded FAQ answers. For any missing detail confirm current figures and state availability with each provider before enrolling.

Final thoughts on Pallas Health vs BreezeMeds

In a direct comparison Pallas Health emphasizes clinician choice between brand-name pens and US-compounded GLP-1s from one intake with a clear compounded intro price of $139 for semaglutide and a 12 week renewal cadence. BreezeMeds highlights injectable and oral options and displays semaglutide starting at $199 but advises confirming eligibility, total cost, renewal terms and state availability. Use the Pallas Health pricing and compounding details if you value a single intake that can deliver either brand or compounded medication with an all-in plan price. Choose BreezeMeds if you need an upfront listing of injectable plus oral format options and will verify the live offer details before enrolling.

Choose Pallas Health if you want a clinician to pick between a brand-name pen and a per-patient compounded preparation and prefer an all-in plan price with compounded semaglutide starting at $139 first month. Choose BreezeMeds if you need injectable and oral GLP-1 formats listed up front and will confirm eligibility pricing and renewal terms directly with the provider. This comparison of Pallas Health vs BreezeMeds uses only the captured source details and advises verifying current pricing and state availability before enrolling.